Literature DB >> 25088730

Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.

Vicente Molina1, Diana Taboada2, María Aragüés2, Juan A Hernández3, Javier Sanz-Fuentenebro4.   

Abstract

Cortical thickness may be useful as a treatment response predictor in first-episode (FE) patients with schizophrenia, although this possibility has been scarcely assessed. In this study we assessed the possible relation between cortical thickness in regions of interest selected because of previously reported structural alterations in schizophrenia and clinical and cognitive changes after two years of treatment with risperidone or clozapine in 31 neuroleptic-naïve FE patients with schizophrenia (16 of them treated with clozapine and 15 with risperidone). Using the last-observation-carried-forward (LOCF), a larger improvement in positive, negative and total symptoms was predicted by the amount of baseline cortical thinning in the right prefrontal cortex (pars orbitalis). After two years of treatment, cognitive status was reassessed in the 17 patients (11 on clozapine) who had not dropped out. Working memory improvement after reassessment was associated with a greater baseline cortical thinning in the left prefrontal cortex (pars orbitalis), and verbal memory improvement with a greater baseline cortical thinning in the left pars triangularis. Significant but weak cortical thickness decrease from baseline to follow-up was observed in patients in comparison to controls (left pars triangularis and opercularis, and left caudal middle frontal areas). These results may support a positive predictive role for cortical thinning in the frontal region with regard to clinical and cognitive improvement with clozapine and risperidone in FE patients with schizophrenia.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clozapine; Cognitive improvement; Cortical thickness; First-episode schizophrenia; Response prediction; Risperidone

Mesh:

Substances:

Year:  2014        PMID: 25088730     DOI: 10.1016/j.schres.2014.06.042

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

2.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

3.  Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.

Authors:  Giulia Tronchin; Theophilus N Akudjedu; Mohamed Ahmed; Laurena Holleran; Brian Hallahan; Dara M Cannon; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2020-04-08       Impact factor: 7.853

4.  Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium.

Authors:  E Walton; D P Hibar; T G M van Erp; S G Potkin; R Roiz-Santiañez; B Crespo-Facorro; P Suarez-Pinilla; N E M Van Haren; S M C de Zwarte; R S Kahn; W Cahn; N T Doan; K N Jørgensen; T P Gurholt; I Agartz; O A Andreassen; L T Westlye; I Melle; A O Berg; L Mørch-Johnsen; A Faerden; L Flyckt; H Fatouros-Bergman; E G Jönsson; R Hashimoto; H Yamamori; M Fukunaga; A Preda; P De Rossi; F Piras; N Banaj; V Ciullo; G Spalletta; R E Gur; R C Gur; D H Wolf; T D Satterthwaite; L M Beard; I E Sommer; S Koops; O Gruber; A Richter; B Krämer; S Kelly; G Donohoe; C McDonald; D M Cannon; A Corvin; M Gill; A Di Giorgio; A Bertolino; S Lawrie; T Nickson; H C Whalley; E Neilson; V D Calhoun; P M Thompson; J A Turner; S Ehrlich
Journal:  Acta Psychiatr Scand       Date:  2017-03-29       Impact factor: 6.392

5.  Impact cérébral structurel et fonctionnel de la Clozapine chez les patients souffrant de schizophrénie : revue systématique des études longitudinales en neuroimagerie.

Authors:  Anaïs Vandevelde; Lucie Métivier; Sonia Dollfus
Journal:  Can J Psychiatry       Date:  2020-11-02       Impact factor: 4.356

6.  Biological Predictors of Clozapine Response: A Systematic Review.

Authors:  Ruta Samanaite; Amy Gillespie; Kyra-Verena Sendt; Grant McQueen; James H MacCabe; Alice Egerton
Journal:  Front Psychiatry       Date:  2018-07-26       Impact factor: 4.157

Review 7.  Verbal memory measurement towards digital perspectives in first-episode psychosis: A review.

Authors:  Can Mişel Kilciksiz; Richard Keefe; James Benoit; Dost Öngür; John Torous
Journal:  Schizophr Res Cogn       Date:  2020-04-15

8.  Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study.

Authors:  Chuan Shi; Shu Qiao Yao; Yi Feng Xu; Jian Guo Shi; Xiu Feng Xu; Cong Pei Zhang; Hua Jin; Xin Yu
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-24       Impact factor: 2.570

9.  Prediction of early response to overall treatment for schizophrenia: A functional magnetic resonance imaging study.

Authors:  Long-Biao Cui; Min Cai; Xing-Rui Wang; Yuan-Qiang Zhu; Liu-Xian Wang; Yi-Bin Xi; Hua-Ning Wang; Xia Zhu; Hong Yin
Journal:  Brain Behav       Date:  2019-01-30       Impact factor: 2.708

10.  Thalamus Radiomics-Based Disease Identification and Prediction of Early Treatment Response for Schizophrenia.

Authors:  Long-Biao Cui; Ya-Juan Zhang; Hong-Liang Lu; Lin Liu; Hai-Jun Zhang; Yu-Fei Fu; Xu-Sha Wu; Yong-Qiang Xu; Xiao-Sa Li; Yu-Ting Qiao; Wei Qin; Hong Yin; Feng Cao
Journal:  Front Neurosci       Date:  2021-07-05       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.